NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, today announced that the Company will
participate in the UBS Global Healthcare Conference in New York, NY.
Chief Financial Officer and Chief Business Officer, Lauren Silvernail,
is scheduled to present on Tuesday, May 22 at 11:00am ET.
Interested parties can access the live audio webcast for this conference
from the Investor Relations section of the company's website at www.revance.com.
The webcast replay will be available after the conclusion of the live
presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with plans to initiate
studies in upper limb spasticity and chronic migraine. RT002 has the
potential to be the first long-acting neuromodulator. Revance has
developed a proprietary, stabilizing excipient peptide technology
designed to create novel, differentiated therapies. The company has a
comprehensive pipeline based upon its peptide technology, including
injectable and topical formulations of daxibotulinumtoxinA. More
information on Revance may be found at www.revance.com."Revance
Therapeutics" and the Revance logo are registered trademarks of Revance
Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180515005135/en/
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert
(714)
325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
Ami Bavishi
(212) 213-0006
abavishi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino
(917) 242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk
(504) 453-8344
nadinepr@gmail.com
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media